Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GMABNASDAQ:ITCINYSE:RDYNASDAQ:RNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGMABGenmab A/S$19.24+2.2%$20.72$18.48▼$30.50$12.73B0.98974,158 shs1.72 million shsITCIIntra-Cellular Therapies$131.87$129.53$64.09▼$131.98$14.05B0.691.47 million shsN/ARDYDr. Reddy's Laboratories$13.24+0.0%$13.36$12.50▼$16.89$11.05B0.481.33 million shs2.38 million shsRNAAvidity Biosciences$28.10-5.6%$31.41$21.56▼$56.00$3.38B1.021.37 million shs2.26 million shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGMABGenmab A/S+2.23%-4.47%-17.53%-10.39%-34.33%ITCIIntra-Cellular Therapies-0.03%+0.09%+0.48%+57.51%+95.89%RDYDr. Reddy's Laboratories-0.11%-0.31%+3.44%-14.28%-9.47%RNAAvidity Biosciences-5.61%-13.70%-1.61%-7.87%+5.48%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGMABGenmab A/S3.8151 of 5 stars4.33.00.00.02.00.03.1ITCIIntra-Cellular Therapies3.5445 of 5 stars2.23.00.04.53.41.70.6RDYDr. Reddy's Laboratories3.3089 of 5 stars3.34.01.70.02.80.01.9RNAAvidity Biosciences2.5654 of 5 stars4.51.00.00.03.80.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGMABGenmab A/S 2.69Moderate Buy$41.33114.83% UpsideITCIIntra-Cellular Therapies 2.33Hold$106.23-19.44% DownsideRDYDr. Reddy's Laboratories 2.50Moderate Buy$17.0028.45% UpsideRNAAvidity Biosciences 3.00Buy$66.69137.34% UpsideCurrent Analyst Ratings BreakdownLatest RNA, ITCI, GMAB, and RDY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/2/2025ITCIIntra-Cellular TherapiesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$132.00 ➝ $132.004/1/2025GMABGenmab A/SSanford C. BernsteinSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeMarket Perform ➝ Underperform3/17/2025RNAAvidity BiosciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.003/17/2025RNAAvidity BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$72.00 ➝ $72.003/17/2025RNAAvidity BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$65.00 ➝ $65.003/13/2025RNAAvidity BiosciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$70.003/12/2025RNAAvidity BiosciencesBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$72.003/11/2025GMABGenmab A/STruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$50.00 ➝ $45.003/11/2025GMABGenmab A/SWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform3/10/2025RNAAvidity BiosciencesBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$51.00 ➝ $48.003/7/2025RNAAvidity BiosciencesScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$70.00(Data available from 4/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGMABGenmab A/S$21.53B0.59$1.30 per share14.80$8.04 per share2.39ITCIIntra-Cellular Therapies$680.50M20.64N/AN/A$6.15 per share21.44RDYDr. Reddy's Laboratories$311.31B0.04$1.00 per share13.25$4.50 per share2.94RNAAvidity Biosciences$10.90M309.99N/AN/A$6.76 per share4.16Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGMABGenmab A/S$1.14B$1.7411.0610.812.6536.30%16.78%13.79%5/1/2025 (Estimated)ITCIIntra-Cellular Therapies-$139.67M-$0.73N/A694.05N/A-14.07%-9.93%-8.38%5/6/2025 (Estimated)RDYDr. Reddy's Laboratories$668M$0.6321.0716.14N/A17.25%17.87%12.32%5/6/2025 (Estimated)RNAAvidity Biosciences-$212.22M-$2.89N/AN/AN/A-2,772.45%-27.66%-24.56%5/8/2025 (Estimated)Latest RNA, ITCI, GMAB, and RDY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2025N/AGMABGenmab A/S$0.26N/AN/AN/AN/AN/A2/27/2025Q4 2024RNAAvidity Biosciences-$0.76-$0.80-$0.04-$0.80$1.74 million$2.97 million2/21/2025Q4 2024ITCIIntra-Cellular Therapies-$0.08-$0.16-$0.08-$0.16$205.08 million$199.22 million2/12/2025Q4 2024GMABGenmab A/S$0.28$0.57+$0.29$0.85$884.02 millionN/A1/23/2025Q3 2025RDYDr. Reddy's Laboratories$0.19$0.20+$0.01$0.20$975.71 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGMABGenmab A/SN/AN/AN/AN/AN/AITCIIntra-Cellular TherapiesN/AN/AN/AN/AN/ARDYDr. Reddy's Laboratories$0.080.60%N/A12.70%N/ARNAAvidity BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGMABGenmab A/SN/A5.255.24ITCIIntra-Cellular TherapiesN/A7.667.51RDYDr. Reddy's Laboratories0.021.921.38RNAAvidity BiosciencesN/A17.7617.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGMABGenmab A/S7.07%ITCIIntra-Cellular Therapies92.33%RDYDr. Reddy's Laboratories3.85%RNAAvidity BiosciencesN/AInsider OwnershipCompanyInsider OwnershipGMABGenmab A/S1.54%ITCIIntra-Cellular Therapies2.60%RDYDr. Reddy's Laboratories2.00%RNAAvidity Biosciences3.68%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGMABGenmab A/S1,660661.77 million651.58 millionOptionableITCIIntra-Cellular Therapies560106.52 million103.56 millionOptionableRDYDr. Reddy's Laboratories24,800834.76 million818.05 millionOptionableRNAAvidity Biosciences190120.21 million114.92 millionOptionableRNA, ITCI, GMAB, and RDY HeadlinesRecent News About These CompaniesAvidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock?April 3 at 10:35 AM | zacks.comAvidity Biosciences, Inc. (NASDAQ:RNA) Shares Bought by Wellington Management Group LLPApril 3 at 5:04 AM | marketbeat.comWhy Avidity Biosciences, Inc.’s (RNA) Stock Is Up 11.33%April 3 at 2:53 AM | aaii.comAvidity Biosciences completes enrollment in Phase 1/2 Fortitude trialApril 2 at 1:35 PM | markets.businessinsider.comPictet Asset Management Holding SA Increases Stock Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)April 2 at 4:31 AM | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Shares Down 7% - Time to Sell?April 1 at 2:00 PM | marketbeat.comAvidity Biosciences to Participate in Upcoming Investor ConferenceApril 1 at 9:00 AM | prnewswire.comAvidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular DystrophyMarch 31, 2025 | prnewswire.comArtisan Partners Limited Partnership Sells 314,028 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)March 30, 2025 | marketbeat.com9,534 Shares in Avidity Biosciences, Inc. (NASDAQ:RNA) Acquired by Quantbot Technologies LPMarch 30, 2025 | marketbeat.comNatixis Advisors LLC Makes New Investment in Avidity Biosciences, Inc. (NASDAQ:RNA)March 28, 2025 | marketbeat.comThe Risk/Reward Of Avidity Biosciences And Its 2 Promising ProgramsMarch 26, 2025 | seekingalpha.comHow Is Avidity Biosciences Inc. (NASDAQ:RNA) Positioned in the Biotech Sector?March 26, 2025 | kalkinemedia.comEFG Asset Management North America Corp. Increases Stock Position in Avidity Biosciences, Inc. (NASDAQ:RNA)March 26, 2025 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Trading 8.5% Higher - Time to Buy?March 25, 2025 | marketbeat.comCibc World Markets Corp Acquires New Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)March 25, 2025 | marketbeat.comSwiss National Bank Acquires 18,800 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)March 25, 2025 | marketbeat.com198,907 Shares in Avidity Biosciences, Inc. (NASDAQ:RNA) Bought by Raymond James Financial Inc.March 25, 2025 | marketbeat.comMagnetar Financial LLC Acquires Shares of 22,003 Avidity Biosciences, Inc. (NASDAQ:RNA)March 23, 2025 | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) CFO Sells $246,461.10 in StockMarch 22, 2025 | marketbeat.comInsider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Sells 9,578 Shares of StockMarch 22, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesSuper Micro's International Presence Makes It a Winning StockBy Gabriel Osorio-Mazilli | March 17, 2025View Super Micro's International Presence Makes It a Winning Stock3 Tech Stocks Defying Sector Weakness and Thriving in 2025By Leo Miller | March 10, 2025View 3 Tech Stocks Defying Sector Weakness and Thriving in 2025How to Build the Ultimate Everything ETF PortfolioBy Jeffrey Neal Johnson | March 16, 2025View How to Build the Ultimate Everything ETF PortfolioModerna: 4 Key Reasons the CEO Just Bought $5M in SharesBy Jea Yu | March 11, 2025View Moderna: 4 Key Reasons the CEO Just Bought $5M in SharesDisney Stock: 4 Key Metrics Validating Its ComebackBy Jea Yu | March 17, 2025View Disney Stock: 4 Key Metrics Validating Its ComebackRNA, ITCI, GMAB, and RDY Company DescriptionsGenmab A/S NASDAQ:GMAB$19.24 +0.42 (+2.23%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$19.37 +0.13 (+0.68%) As of 04/3/2025 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Intra-Cellular Therapies NASDAQ:ITCI$131.87 0.00 (0.00%) As of 04/2/2025Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.Dr. Reddy's Laboratories NYSE:RDY$13.24 +0.01 (+0.04%) Closing price 04/3/2025 03:59 PM EasternExtended Trading$13.25 +0.02 (+0.11%) As of 04/3/2025 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.Avidity Biosciences NASDAQ:RNA$28.10 -1.67 (-5.61%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$28.98 +0.88 (+3.13%) As of 04/3/2025 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom’s VMware Strategy Could Fuel the Next AVGO Rally Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy? Celsius Heats Up: Acquisition, Analyst Upgrade Fuel Momentum 5 Reasons Why Halliburton Is a Good Buy in 2025 First Watch Restaurant Group: A First-Rate Small-Cap Growth Stock Tesla Stock: What To Expect With Their Delivery Numbers Report Rocket Lab: $5.6 Billion Defense Contract Fuels RKLB’s Future Equinix: A Smart Bet on Data Centers, Dividends, and AI Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
